Page 1

Paltamira therapeutics Altamira Therapeutics Provides Update on Bentrio Program September 27 , 2021 11:45 AM EDT • Building Bentrio ™ brand and expanding in European markets . 510 ( k ) premarket notification for allergy indication submitted to the U.S. Food and Drug Administration ( " FDA " ) • Distributors signed up for two key South East Asian countries , highlighting international expansion potential HAMILTON , BERMUDA / ACCESSWIRE / September 27 , 2021 / Altamira Therapeutics Ltd. ( NASDAQ : CYTO ) , a company dedicated to addressing unmet medical needs through RNA therapeutics , allergy and viral infection protection , and inner ear therapeutics , today provided a business update on Bentrio ™ , its nasal spray for protection against airborne viruses and allergens . Bentrio ™ was launched first in Germany under CE mark in late July and subsequently also in Austria . During the initial launch stage , the nasal spray product has been marketed solely through leading online pharmacies , supported by digital campaigns combined with classic instruments . The Bentrio.com website is currently receiving approximately 2,500 visitors per day in Germany , and traffic is continuing to grow . Promotional activities are being progressively expanded to further European countries . In the next phase of the European launch of Bentrio ™ , starting in Q4 2021 , the Company will also target traditional ' brick - and - mortar ' pharmacy stores . With the goal of accessing the large potential U.S. market for Bentrio TM , the Company has recently submitted a 510 ( k ) premarket notification to the FDA . The claimed use for Bentrio TM is the treatment of hay fever and allergy sufferers by promoting alleviation of mild allergic symptoms triggered by the inhalation of various airborne allergens . These include indoor and outdoor environmental pollens , house dust , animal hair and dust mites . Once cleared , the Company anticipates partnering Bentrio ™ for the U.S. market rather than commercializing it there on its own . Altamira also sees significant business development opportunities for Bentrio ™ in international markets . In that regard , the Company recently executed letters of understanding with distributors in two key Southeast Asian countries , with national registrations being initiated . Based on a growing number of leads and strong interest in the product , Altamira expects to expand the geographic footprint for Bentrio ™ rapidly through agreements with additional distributors . Concurrent with the commercial activities outlined above , the Company is also advancing its clinical development programs for Bentrio ™ . In allergy , two studies are moving through the approval process : one for house dust allergy as a challenge study , and another for seasonal allergic rhinitis . These studies will be conducted in Canada and Australia , with data read - outs expected for Q1 and Q2 2022. In viral infection , Altamira is awaiting the approval of a placebo - controlled COVID - 19 study by the Drugs Controller General of India . " While we have been making significant progress in all of our development programs , in many ways , we just recently crossed the starting line , with the European launch of Bentrio TM marking our transition to a commercial - stage company , " commented Thomas Meyer , Altamira Therapeutics ' founder , Chairman and CEO . " Now , based on the early success we are seeing in Germany , our focus for the product will be on both geographic and treatment market expansion . We look forward to updating our stakeholders as we progress . " Conference Call & Webcast Details Alamira is pleased to invite all interested parties to participate in a conference call today at 8:00 AM Eastern Time , during which more details will be provided on its Bentrio TM commercial , development and regulatory activities and plans . To participate telephonically , please dial ( 888 ) 506-0062 ( U.S. ) or ( 973 ) 528-0011 ( international ) , conference code 590321. A live , listen - only webcast of the conference call , which will include accompanying slides , can be accessed by visiting the Company's website at www.altamiratherapeutics.com under " Events & Presentations " in the " Investors & Media " section . An archive of the webcast will also be available following the conclusion of the conference call . About Bentrio ™ M Bentrio ™ M ( AM - 301 ) is a drug - free nasal spray intended for personal protection against airborne viruses and allergens . Upon application into the nose , Bentrio ™ forms a protective gel layer on the nasal mucosa . This thin film is designed to prevent the contact of viruses or allergens with cells ; in addition , the composition serves to bind such particles and help with their discharge and to humidify the nasal mucosa . Together , this is designed to reduce the risk of upper respiratory tract viral infections and promote alleviation of allergic symptoms . In human nasal epithelium cells infected by SARS - CoV - 2 , Bentrio TM was shown to reduce the infectious viral load by more than 99 % when used for prevention . Further , Bentrio TM was effective in slowing the growth of the viral titer when treatment started only 24 or 30 hours after infection . In allergy , a clinical investigation in a pollen challenge chamber demonstrated a significant reduction in the main symptoms of allergic rhinitis with the protective effect setting in rapidly and lasting for 4 hours . About Altamira Therapeutics Altamira Therapeutics is dedicated to developing therapeutics that address important unmet medical needs . The Company is currently active in three areas : the development of RNA therapeutics for extrahepatic therapeutic targets ( OligoPhore TM / Semaphore TM platforms ; preclinical ) , nasal sprays for protection against airborne viruses and allergens ( Bentrio TM ; commercial ) or the treatment of vertigo ( AM - 125 ; Phase 2 ) , and the development of therapeutics for intratympanic treatment of tinnitus or hearing loss ( KeyzilenⓇ and SonsuviⓇ , Phase 3 ) . The Company was founded in 2003 and is headquartered in Hamilton , Bermuda with its main operations in Basel , Switzerland . The shares of Altamira Therapeutics Ltd. trade on the NASDAQ Capital Market under the symbol " CYTO . " Forward - looking Statements